MATRISOME BIO, INC.

Matrisome Bio is a seed-stage biotech company developing a novel class of targeted cancer therapies that deliver potent payloads directly to the extracellular matrix (ECM) of tumors and metastases. Rather than targeting individual cancer cell mutations, the company's nanobody-based platform binds to disease-associated ECM proteins that are abundant, stable, and highly conserved across tumor types — converting the matrix into a high-retention drug depot for multi-modal therapeutic delivery including radioligand therapy (RLT). The approach is pan-tumor applicable and spares healthy tissue. Founded by CEO Noor Jailkhani, Richard Hynes, and Sangeeta Bhatia, Matrisome Bio's initial focus is metastatic solid tumor oncology with planned expansion into fibrosis and cardiovascular disease. The company has received NIH SBIR funding and is backed by Engine Ventures.